Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5549563 | 0.98 | MEN1 (0.50) | MAOAMAOBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2992329 | 0.90 | ALDH1A1 (0.52) | MAOACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2997554 | 0.89 | ALDH1A1 (0.53) | MAOBCYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL1155719 | 0.88 | ALDH1A1 (0.55) | MAOAMAOBCYP3A4MEN1KMT2A | |
| SCHEMBL29688467 | 0.88 | ALDH1A1 (0.55) | MAOAMAOBCYP3A4MEN1KMT2A | |
| SCHEMBL3003478 | 0.88 | ALDH1A1 (0.55) | MAOAMAOBCYP3A4MEN1KMT2A | |
| SCHEMBL31457276 | 0.88 | ALDH1A1 (0.55) | MAOAMAOBCYP3A4MEN1KMT2A | |
| SCHEMBL7569937 | 0.87 | MAOB (0.55) | MAOBCYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL29764012 | 0.86 | ALDH1A1 (0.50) | CYP3A4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL23850 | 0.86 | ALDH1A1 (0.50) | CYP3A4MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854967-A | High-temperature energy storage fluorine-containing aromatic polyamide dielectric film and preparation method thereof | 四川大学 | 2023-10-10 | — | — | CN | claimed |
| EP-0446719-A1 | Amino phenoxy compounds and process for their preparation | Bromine Compounds Ltd. (IL) | 1991-09-18 | — | — | EP | claimed |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | GEN1E LIFESCIENCES INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085745-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| CN-111819172-B | Triazine derivatives for the treatment of neurotrophin related diseases | 阿泽克制药公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-116854967-A | High-temperature energy storage fluorine-containing aromatic polyamide dielectric film and preparation method thereof | 四川大学 | 2023-10-10 | — | — | CN | disclosed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1134214-A1 | PICOLINAMIDE DERIVATIVES AND PEST CONTROLLERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5631401-A | Inhibitors of protein farnesyltransferase and squalene synthase | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5344986-A | Intermediates for polymers | BROMINE COMPOUNDS, LTD. (IL) | 1994-09-06 | — | — | US | disclosed |
| EP-0446719-A1 | Amino phenoxy compounds and process for their preparation | Bromine Compounds Ltd. (IL) | 1991-09-18 | — | — | EP | disclosed |
| US-4141881-A | PERYLENE-3,4,9,10-TETRACARBOXYLIC PIGMENT MIXTURE WITH DYE | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, CDC42BPG | MAOA 3206/4885MAOB 3363/4885CYP1A2 4832/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | MAOA 4252/4885MAOB 3414/4885CYP1A2 2636/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MAOA 126/4885MAOB 104/4885CYP1A2 2565/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | MAOA 1813/4885MAOB 1185/4885CYP1A2 3782/4885 |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | CDC42BPG, GRK3, ERBB2 | MAOA 4479/4885MAOB 3970/4885CYP1A2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.